Oncolytics Biotech, Inc.

Twitter LinkedIn
  • Home
  • About
    • Our Company
    • Management Team
    • Board of Directors
  • Technology
    • What is Pelareorep?
    • What Does Pelareorep Do?
    • Delivery
    • Intellectual Property
    • Posters & Publications
    • Manufacturing
  • Clinical Trials
    • Clinical Development Plan
    • Collaborators
    • Pipeline
  • Media
    • Press Releases
    • Insights
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Stock Information
    • Filings & Financials
    • Corporate Governance
    • FAQs
    • Email Alerts
    • IR Contacts
  • Contact
  • Careers

Press Releases

Investors

Investors

  • Overview
  • Press Releases
  • Events & Presentations
  • Stock Info
    • Snapshot
    • Quote (Nasdaq)
    • Charts (Nasdaq)
    • Historical Data (Nasdaq)
    • Quote (TSX)
    • Charts (TSX)
    • Historical Data (TSX)
    • Analyst Coverage
  • Filings & Financials
    • Reports
    • SEC Filings
    • SEDAR Filings
    • Tax Information (PFIC)
  • Corporate Governance
  • FAQs
  • Email Alerts
  • IR Contacts
Jul 27, 2022

Oncolytics Biotech® to Host Conference Call to Discuss Second Quarter Financial Results and Recent Operational Highlights

Jun 28, 2022

Oncolytics Biotech® Achieves Success Criteria for Efficacy in the Pancreatic Cancer Cohort of GOBLET

Jun 17, 2022

Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders and Appoints James T. Parsons to its Board of Directors

May 10, 2022

Oncolytics Biotech® to Participate in a Fireside Chat at the 2022 RBC Capital Markets Global Healthcare Conference

May 5, 2022

Oncolytics Biotech® Reports First Quarter 2022 Financial Results and Recent Operational Highlights

May 4, 2022

Oncolytics Biotech® and SOLTI Present New Clinical Biomarker Data Demonstrating Pelareorep's Potential to Improve the Prognosis of Breast Cancer Patients at the ESMO Breast Cancer Meeting

May 2, 2022

Oncolytics Biotech® and SOLTI Announce Upcoming Poster Presentation at the European Society for Medical Oncology Breast Cancer Meeting

Apr 28, 2022

Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights

Apr 21, 2022

Oncolytics Biotech® to Present at the Bloom Burton & Co. Healthcare Investor Conference

Apr 14, 2022

Oncolytics Biotech® Announces Publication of Preclinical Data Demonstrating the Synergistic Anti-Cancer Activity of Pelareorep Combined with CAR T Cell Therapy in Solid Tumors in Science Translational Medicine

RSS
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • ...59
    © 2023 Oncolytics Biotech, Inc. All Rights Reserved.
    Privacy Policy Disclaimer Sitemap